ROSEVILLE, Minnesota — EnteroMedics Inc. already faces plenty of doubters on Wall Street. So not surprisingly, the company was not too happy with a recent story I wrote suggesting Leptos Biomedical Inc.’s demise had something to do with EnteroMedics’s problems with the Food and Drug Administration.
EnteroMedics and Leptos are both developing a device that uses electricity to treat obesity. But that’s where the similarities end, EnteroMedics CEO Mark Knudson told me in a quick phone call.
“I see no connection,” he said.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
In the story, I wrote EnteroMedics’ problems with gaining FDA approval for its VBLOC therapy spelled bad news for companies like Leptos, who are far behind EnteroMedics in clinical development. I theorized EnteroMedics’ FDA woes spooked investors in the competition.
If EnteroMedics fails to win regulatory approval, companies following it will no doubt face a tough time raising money, Knudson said. But Leptos’ demise probably had a more simple reason: Its technology didn’t work, he said.
Leptos CEO Hans Neisz declined to tell me why the company folded, except to say it had nothing to do with raising money.
I should note that Knudson, who was gracious and friendly, invited me to visit his company next month. I gladly accepted.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.